The 2011 vitamin D recommendations set by the Food and Nutrition Board of the Institute of Medicine was the first time that Estimated Average Requirements (EAR) and Recommended Dietary Allowance (RDA) were given for vitamin D. Previous versions (i.e., 1997 and earlier) used Adequate Intakes, implying less certainty of evidence to determine the EAR. It is difficult to set requirements for vitamin D because it behaves more like a hormone than a nutrient and because diet is not the only source of vitamin D. In fact, more vitamin D comes from cutaneous production than from diet for most people. Therefore, one cannot use the common factorial approach of estimating daily losses adjusted by absorption and needs during growth to set intake recommendations. The basis for the 2011 vitamin D recommendations was for bone health. Systematic reviews showed vitamin D status levels associated with calcium absorption, bone mineral density, and risk of osteomalacia or rickets. An integrated model was used to set vitamin D status, measured by serum 25-hydroxyvitamin D (25(OH)D) levels, at 40 nM for the EAR and 50 nM for the RDA. Vitamin D intakes to achieve these levels became the recommended intakes based on a nonlinear model of the relationship of vitamin D intake and achieved serum 25(OH)D levels. The panel assumed all vitamin D intakes should come from diet in their recommendations because many groups are not exposed to UVB light, are elderly or are dark skinned, which limits cutaneous production. However, intakes are well below recommended levels. Clinical guidelines for patients at risk for vitamin D deficiency were also established in 2011 by the Endocrine Society, which gives physicians more latitude for vitamin D recommendations.
INTRODUCTION
Vitamin D is one of the most studied nutrients being studied currently. Adequate vitamin D status, as commonly measured by serum 25-hydroxyvitamin D (25(OH)D) , has been linked to both proper paracrine and autocrine functions and a reduced risk of many diseases including osteoporosis, diabetes, several cancers, and immune function disorders such as multiple sclerosis, allergies, influenza, eczema, infection, etc. Moreover, interest in vitamin D has spread to the general public, which has demanded to know their vitamin D status and how to ensure adequacy from health care providers. Interest in vitamin D status has extended to companion animals and production animal agriculture.
One of the 4 shortfall nutrients identified by the 2010 Dietary Guidelines for Americans Committee (2011) was vitamin D. This is because average intakes of the population are about one-half or less of recommended intakes. The deficiency increases across the age groups as intakes rise. Much of vitamin D input can come from cutaneous production. However, recommendations for dietary intakes assume all vitamin D comes from the diet. The extent to which cutaneous production can be expected to contribute to vitamin D and the relationship of vitamin D status to functional indicators of health are sources of great controversy. It is in this context that the basis for the current requirements need to be understood to interpret health consequences and to set the agenda for future research.
SETTING THE DIETARY REFERENCE INTAKES
The Dietary Reference Intakes (DRI) are determined for essential nutrients by the Food and Nutrition Board of the Institute of Medicine (IOM; 2006) . Dietary Reference Intakes include intakes for the Estimated Average Requirements (EAR) for a population, the Recommended Dietary Allowance (RDA) that includes a safety margin to ensure adequacy for most (approximately 98%) of the population, and the upper level (UL) to avoid risk of excess intake as depicted in Fig. 1 . The 2011 DRI for vitamin D was the first time an EAR and a RDA were set for vitamin D (IOM, 2011) . Before that, Adequate Intake was given for vitamin D because the panel judged that there was insufficient evidence to set an EAR. The EAR is the most useful indicator for evaluating adequacy of intakes because it can be used to determine the proportion of a population who do not meet the EAR, and therefore are at risk of being insufficient in a nutrient. Use of the RDA to attempt to determine inadequacy of a population overestimates deficiency. The Adequate Intake is an intake assumed to be adequate for a healthy population. This approach is often used for nutrients in breast milk under the assumption that breast milk is designed to be adequate to nourish the growing infant. This assumption is generally true for many nutrients that tend to be present in constant concentration regardless of the diet of the mother, as for minerals. However, vitamin D in breast milk varies with the status of the mother so recommended intakes for breast-fed infants can be so low as to lead to rickets in the child as they become a toddler. As a consequence, the American Academy of Pediatrics and the Canadian Pediatric Association both recommend universal supplementation to provide 400 IU/d of vitamin D (Wagner et al., 2008) . Of course, infants may be born with vitamin D deficiency and present with infantile rickets that is unrelated to vitamin D deficiency in mother's milk. Lactating women given 4,000 to 6,000 IU/d vitamin D would provide adequate vitamin D to meet the needs of infants (Hollis and Wagner, 2004) , but most human milk has lower levels of vitamin D, on average 15.9 ± 8.6 IU/L.
Typical approaches for estimating average requirements are listed in Table 1 . The factorial approach is a classic approach for setting mineral requirements. This approach involves adding the needs for tissue development as occurs during growth, pregnancy, and lactation to obligatory losses as occurs through the urine, stools, and skin and adjusted for absorption efficiency. The values for loss and absorption efficiency can be determined through classical balance studies. A difficulty with the factorial approach is that many of these parameters change with intake. Therefore, they need to be determined on a range of intakes. When these data are available, it is possible to determine the intakes for maximal retention, which has only been done for calcium by the 1997 IOM Panel (IOM, 1997) .
Neither the factorial or threshold intake for maximal retention can be used for a hormone such as vitamin D. The intake assumed to be adequate for a healthy population (the Adequate Intake) was used until the 2011 panel revised the value to an EAR as the panel determined there were sufficient data to determine adequacy based on a functional indicator.
The 2011 IOM panel determined that there was sufficient evidence for determining an EAR and RDA for vitamin D status for bone health indicators including calcium absorption efficiency, bone mineral density (BMD), and fracture risk. Other health indicators besides bone were evaluated but the evidence was deemed insufficient to set requirements for vitamin D. The first step was to determine the relationship of vitamin D status to the various bone health outcome measures. Serum 25(OH)D is the best indicator of vitamin D status because it reflects input from both diet and cutaneous production, is not readily degraded, and is not a homeostatic regulator the way serum 1,25-dihydroxyvitamin D responds rapidly to serum calcium status. Data for the relationship of serum 25(OH)D to various bone health parameters were modeled (Fig. 2 ). Using this model, it was determined that a reasonable EAR for vitamin D status is 40 nM and a cor- responding RDA is 50 nM. Fractional calcium absorption is maximized at levels much less than that (Need et al., 2002; Hansen et al., 2008) . Subsequent dose-response studies of vitamin D supplementation showed no increase in fractional calcium absorption or parathyroid hormone suppression in children (Lewis et al., in press ), young women (Gallagher et al., 2013b) , or elderly white (Gallagher et al., 2012) or black (Gallagher et al., 2013a) women. Risk of rickets is also reduced at lower levels (Cranney et al., 2007) . The panel relied greatly on the Agency for Healthcare Research and Quality systematic reviews to determine optimal values for BMD and fracture risk (Cranney et al., 2007; Chung et al., 2009) . A subsequent report (Cauley et al., 2011) supports the IOM panel for protecting against fracture risk in elderly whites, but fracture risk in blacks was not reduced by increasing vitamin D status above 30 nM serum 25(OH)D.
Much less evidence exists to determine the EAR and RDA for children. One of the few vitamin D dose response studies in children was a 1-yr trial of changes in serum 25(OH)D levels and bone gain in adolescent girls in Finland (Viljakainen, 2006) . Vitamin D status increased and bone gain increased with supplementation of 200 or 400 IU/d. However, vitamin D status is likely lower in the northern latitudes of Finland compared with the United States. Recently, we conducted a dose-response study of up to 4,000 IU/d in early pubertal black and white children during winter months and found serum 25(OH)D responded to dose, but no functional outcome measure, including fractional calcium absorption, was improved (Lewis et al., 2013) . This indicates that vitamin D was adequate in healthy U.S. adolescents living in both the northern and southern latitudes of Indiana and Georgia. One study in adolescent boys and girls did show an impact on blood flow with 2,000 IU/d supplementation (Dong et al., 2010) Moving from vitamin D status (i.e., serum 25(OH)D) to recommendations for vitamin D intake is a challenge when most of the input comes from cutaneous production. Furthermore, the relationship between vitamin D intake and serum 25(OH)D levels is not linear. The plateau at higher levels is indicative of adipocyte storage. Therefore, intakes to alter serum 25(OH)D to a target level cannot be computed with a simple conversion factor.
The IOM panel set intakes for various age groups as shown in Table 2 . They assumed no cutaneous production as the supply is variable so recommendations are based on coming from diet exclusively. Populations at risk for inadequate cutaneous production include the elderly, individuals with dark skin, individuals living in temperate latitudes and higher, invalids and shut-ins, and others who are not exposed to UVB radiation.
ENDOCRINE SOCIETY CLINICAL GUIDELINES
The Endocrine Society (Chevy Chase, MD) assembled a task force to set vitamin D clinical guidelines (Holick et al., 2011) during the same time as the IOM panel was determining DRI for the generally healthy population. The clinical guidelines were intended for clinicians who treat patients at risk for vitamin D deficiency. The goals and process for the 2 guidelines were very different. A clinician has the ability to monitor vitamin D status of the individual patient and has access to their complete health records and family incidence of disease. Unlike the IOM panel who met multiple times over 2 yr with considerable staff support and evidence evaluated from multiple systematic reviews, costing approximately US$2 million, the Endocrine Society task force met only by conference calls. The process cost little and did not have separate systematic reviews on patient populations to guide them. Their guidelines included much advice for bringing overtly deficient patients to an adequate level. A comparison of the guidelines to the IOM recommendations is shown in Table 2 .
SOURCES OF DIETARY VITAMIN D
Few natural foods contain adequate vitamin D to meet vitamin D recommendations (Wacker and Holick, 2013) . Fatty fish are a good source, but few people outside of Scandinavia ingest enough fatty fish to meet their recommended intakes. Fortified foods provide about 70% of the vitamin D in the diet. Fortified milk is the largest dietary source of vitamin D in the United States and is supplemented at 100 IU/240 g. In the U.S. population, body mass index status, use of sun protection, and milk intake were the largest predictors of vitamin D status (Looker et al., 2008) . Newer sources of vitamin D that were shown to be bioavailable and safe are UVB-irradiated yeast and mushrooms ( al., 2013). Yeast and mushrooms provide ergocalciferol or vitamin D 2 in contrast to animal sources that provide cholecalciferol or vitamin D 3 . Both sources are bioactive, but there is considerable debate over their relative potency. In single dose studies, vitamin D 2 is cleared from serum more quickly than vitamin D 3 , but the IOM panel (IOM, 2011) concluded that at low doses, the 2 forms are equipotent, as illustrated by Holick et al. (2008) . In a rat study, crystalline vitamin D 3 was found to increase serum 25(OH)D more than twice that of bread made with yeast irradiated with UVB, but that the 2 sources were equal in their ability to enhance bone acquisition (Hohman et al., 2011) . The level of vitamin D fortification allowed by the U.S. Food and Drug Administration in fortified foods is given in Table 3 
UPPER LEVELS
Safety of vitamin D is usually monitored by evidence of hypercalcemia or hypercalciuria. The UL is an intake level below which is considered tolerable. The levels recommended for safety by the IOM panel and Endocrine Practice Guidelines Committee were quite different ( Table 2 ). The no observed-adverse-effect level (NOAEL) for rise in serum calcium is 10,000 IU/d. An excellent review of the safety of vitamin D is Hathcock et al. (2007) , which supports a UL of 10,000 IU/d. The IOM panel took a more conservative view than the Endocrine Practice Guidelines Committee for the general population. The panel reasoned that there is adequate evidence that 10,000 IU/d for 6 mo is safe, but since vitamin D is stored in adipose tissue, longer periods of exposure may be toxic. They applied an uncertainty factor of 2, which reduced the UL to 5,000 IU/d and then further reduced it by 20% to 4,000 IU/d for Americans over age 9 yr because of uncertainty of risk of all-cause mortality in blacks. An analysis of NHANES data in Americans showed a U-shaped relationship between serum 25(OH) D levels all age-adjusted all-cause mortality where the nadir occurred at a lower vitamin D status in African Americans than in white Americans (IOM, 2011) .
The UL is meant to discourage individuals from exceeding safe intake through oversupplementation unless carefully monitored by their physician. But UL also have the consequence of limiting allowable fortification levels. The U.S. Food and Drug Administration makes decisions on limits to fortify foods by calculating possible intakes through diet if all fortified foods were chosen. The doubling of the UL to 4,000 IU/d by the 2010 IOM panel paved the way to higher levels of food fortification.
SUMMARY AND CONCLUSIONS
An EAR and RDA were first established for vitamin D in 2010 by the IOM and the UL was doubled. Most Americans do not consume the recommended intakes (Fig. 3) and rely on cutaneous synthesis to achieve recommended serum 25(OHO)D levels. However, many Americans do not have sufficient cutaneous production. Newer sources of fortified foods can help and physicians can take more aggressive approaches to treat patients at risk for vitamin D insufficiency.
Current vitamin D recommendations are based on bone-related outcome measures. Newer data indicate that vitamin D supplementation does little to improve calcium absorption or bone mineral density in the generally healthy American population. Dose-response studies for nonskeletal health benefits are needed. 
